Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid entities : Vir biotechnology, inc. save search
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.36%
H: 0.46%
C: 0.46%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -4.59%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
covid-19 treatment europe granted covid authorization grant
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Published: 2021-12-07 (Crawled : 14:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 6.57%
H: 14.77%
C: 11.21%
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 0.37%
H: 10.37%
C: 9.63%
covid vaccine
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published: 2021-11-17 (Crawled : 12:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.43%
H: 2.31%
C: 2.27%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 9.97%
H: 4.0%
C: -6.28%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
covid treatment biotech technology iot covid-19
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.06%
H: 1.31%
C: 1.02%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.54%
H: 4.68%
C: 0.14%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.5%
H: 1.7%
C: 1.4%
covid treatment europe biotech technology iot covid-19
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published: 2021-05-26 (Crawled : 23:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.8%
H: 0.69%
C: 0.23%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 4.2%
H: 0.3%
C: -9.4%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid treatment fda risk biotech technology iot merge authorized emergency use authorization
CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 12:15) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
Published: 2021-05-07 (Crawled : 14:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.5%
H: 0.84%
C: 0.66%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.48%
H: 0.74%
C: 0.31%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 3.24%
H: 2.94%
C: 0.02%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.92%
H: 0.88%
C: 0.66%
covid treatment biotech technology iot ema
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
Published: 2021-04-15 (Crawled : 14:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 4.23%
H: 1.59%
C: 0.08%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 0.37%
H: 2.8%
C: -1.49%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.76%
H: 0.61%
C: 0.14%
covid treatment antibody biotech technology iot ema
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Published: 2021-03-29 (Crawled : 14:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.82%
H: 1.18%
C: 0.88%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.63%
C: 0.91%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.46%
H: 1.02%
C: -4.73%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.57%
covid phase 2 risk positive topline biotech technology iot trial
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
Published: 2021-03-26 (Crawled : 13:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.28%
H: 2.0%
C: 1.95%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.52%
H: 1.01%
C: 0.68%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.27%
H: 1.56%
C: -3.45%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.31%
H: 1.33%
C: 1.22%
covid treatment fda biotech technology iot merge submission authorized emergency use authorization
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
Published: 2021-03-11 (Crawled : 02:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.67%
H: 0.96%
C: 0.54%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.52%
H: 0.36%
C: -0.63%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 44.57%
H: 0.75%
C: -8.66%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.31%
H: 0.63%
C: 0.08%
covid treatment risk biotech iot
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Published: 2021-03-03 (Crawled : 15:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.26%
H: 0.93%
C: 0.71%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -28.99%
H: 8.39%
C: 1.9%
covid biotech iot trial
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.12%
H: 0.1%
C: -1.6%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.78%
H: 0.45%
C: -1.66%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -7.13%
H: 96.21%
C: 15.59%
covid ev biotech trial
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Published: 2021-01-12 (Crawled : 08:03) - globenewswire.com
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.29%
H: 0.21%
C: -0.95%
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.91%
H: 16.28%
C: 11.28%
covid biotech treatment
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Published: 2020-12-17 (Crawled : 21:05) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 0.83%
H: 1.43%
C: -6.46%
covid biotech trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.